Research ExplorerJournalsLANCET HIV Publications

LANCET HIV - Lancet HIV

1 - 2 out of 2Page size: 50

Publications

  1. 2022

  2. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

    Turkova, A., Waalewijn, H., Chan, M. K., Bollen, P. D. J., Bwakura-Dangarembizi, M. F., Kekitiinwa, A. R., Cotton, M. F., Lugemwa, A., Variava, E., Ahimbisibwe, G. M., Srirompotong, U., Mumbiro, V., Amuge, P., Zuidewind, P., Ali, S. S., Kityo, C. M., Archary, M., Ferrand, R. A., Violari, A., Gibb, D. M., Burger, D., Ford, D., Colbers, A. & ODYSSEY Trial Team, 09.2022, In: LANCET HIV. 9, 9, p. E627-E637

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  3. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

    Amuge, P., Lugemwa, A., Wynne, B., Mujuru, H. A., Violari, A., Kityo, C. M., Archary, M., Variava, E., White, E., Turner, R. M., Shakeshaft, C., Ali, S., Nathoo, K. J., Atwine, L., Liberty, A., Bbuye, D., Kaudha, E., Mngqibisa, R., Mosala, M., Mumbiro, V., Nanduudu, A., Ankunda, R., Maseko, L., Kekitiinwa, A. R., Giaquinto, C., Rojo, P., Gibb, D. M., Turkova, A., Ford, D. & ODYSSEY Trial Team, 09.2022, In: LANCET HIV. 9, 9, p. e638-e648

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review